Zenocutuzumab（Cat No.:I042139）is an investigational monoclonal antibody that targets the protein HER2 (human epidermal growth factor receptor 2) and its co-receptor, HER3, both of which are implicated in cancer cell signaling and tumor growth. HER2 overexpression is common in cancers like breast, gastric, and non-small cell lung cancer (NSCLC). Zenocutuzumab aims to block the interaction between HER2 and HER3, disrupting tumor growth and enhancing immune response against cancer cells. It is being studied in clinical trials for its potential to treat HER2-positive cancers, with a focus on improving patient outcomes in solid tumors.
